Aura Biosciences, Inc. (AURA)
NasdaqGM · USD · Healthcare · Biotechnology
$6.22 (+0.65%) as of
Key statistics
- Market cap
- 645.04M
- Forward P/E
- -3.06
- EPS (TTM)
- -1.75
- Dividend yield
- 0.00%
- 52-week range
- 4.73 – 9.53
- Beta
- 0.41
- Profit margin
- 0.00%
- Analyst target
- $16.60
- Volume
- 81.91k
About Aura Biosciences, Inc.
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Boston, MA, United States
- Employees
- 113
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.